PELLEGATA, NATALIA SIMONA
 Distribuzione geografica
Continente #
NA - Nord America 2.224
AS - Asia 1.255
EU - Europa 1.072
SA - Sud America 189
AF - Africa 107
Continente sconosciuto - Info sul continente non disponibili 75
OC - Oceania 3
Totale 4.925
Nazione #
US - Stati Uniti d'America 2.120
CN - Cina 449
SG - Singapore 300
IT - Italia 231
HK - Hong Kong 207
IE - Irlanda 201
BR - Brasile 142
RU - Federazione Russa 139
VN - Vietnam 113
DE - Germania 110
FR - Francia 93
FI - Finlandia 79
ZA - Sudafrica 78
UA - Ucraina 66
GB - Regno Unito 49
CA - Canada 44
BD - Bangladesh 33
SE - Svezia 31
IN - India 30
MX - Messico 17
JP - Giappone 15
IQ - Iraq 14
TR - Turchia 14
AR - Argentina 13
ES - Italia 13
NL - Olanda 12
AT - Austria 11
PL - Polonia 11
CO - Colombia 10
ID - Indonesia 10
PK - Pakistan 10
SA - Arabia Saudita 9
BE - Belgio 8
CR - Costa Rica 7
EC - Ecuador 6
EG - Egitto 6
GP - Guadalupe 6
KE - Kenya 6
LT - Lituania 6
PH - Filippine 6
SV - El Salvador 6
CL - Cile 5
JO - Giordania 5
MA - Marocco 5
GT - Guatemala 4
IL - Israele 4
PR - Porto Rico 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
UZ - Uzbekistan 4
KG - Kirghizistan 3
KH - Cambogia 3
KZ - Kazakistan 3
MY - Malesia 3
PE - Perù 3
SC - Seychelles 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BO - Bolivia 2
CH - Svizzera 2
ET - Etiopia 2
HN - Honduras 2
IR - Iran 2
IS - Islanda 2
JM - Giamaica 2
KR - Corea 2
LK - Sri Lanka 2
LV - Lettonia 2
NI - Nicaragua 2
PA - Panama 2
PY - Paraguay 2
VE - Venezuela 2
AM - Armenia 1
AU - Australia 1
BB - Barbados 1
CD - Congo 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EU - Europa 1
GD - Grenada 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
HT - Haiti 1
LB - Libano 1
MU - Mauritius 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PF - Polinesia Francese 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SR - Suriname 1
TN - Tunisia 1
Totale 4.851
Città #
San Jose 241
Hong Kong 202
Ashburn 198
Dublin 198
Chandler 187
Council Bluffs 167
Singapore 147
Dallas 141
Beijing 124
Boardman 75
Johannesburg 71
Jacksonville 64
Lauterbourg 57
Nanjing 57
Los Angeles 56
Helsinki 46
Ho Chi Minh City 39
Lawrence 33
Moscow 33
Redondo Beach 33
Princeton 32
Santa Clara 31
Medford 30
Milan 29
Wilmington 29
Munich 28
Falkenstein 26
Hanoi 24
New York 24
Florence 23
Rome 20
Hebei 19
Columbus 18
Jiaxing 18
Shanghai 18
Buffalo 17
Chicago 17
Nanchang 17
São Paulo 16
The Dalles 16
Phoenix 14
Shenyang 14
Tokyo 14
Atlanta 13
Changsha 13
Montreal 13
Monza 13
Toronto 13
Brooklyn 12
Chennai 12
Da Nang 12
Orem 12
Seattle 12
Pavia 11
Tianjin 11
Denver 10
Ann Arbor 9
Germering 9
Brussels 8
Istanbul 8
Naples 8
North Bergen 8
San Francisco 8
Bologna 7
Boston 7
Frankfurt am Main 7
Rio de Janeiro 7
Secaucus 7
Warsaw 7
Genoa 6
Guangzhou 6
Newark 6
San José 6
Verona 6
Amman 5
Biên Hòa 5
Cape Town 5
Haiphong 5
Houston 5
Kolkata 5
Nairobi 5
Padova 5
Queens 5
San Salvador 5
Turin 5
Vienna 5
Carbonara Scrivia 4
Caserta 4
Curitiba 4
Córdoba 4
Dhaka 4
Falls Church 4
Hangzhou 4
Jakarta 4
Mosul 4
Philadelphia 4
Tashkent 4
The Bronx 4
Washington 4
Alessandria 3
Totale 3.065
Nome #
Analysis and clinical implications of K-ras gene mutations and infection with human papillomavirus types 16 and 18 in primary adenocarcinoma of the uterine cervix 165
Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions 140
K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma 137
The novel SSTR3 full agonist ITF2984 shows antitumor properties against pancreatic neuroendocrine tumors (Pan-NETs) 126
K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions 125
Primary retroperitoneal mucinous cystoadenocarcinomas: an immunohistochemical and molecular study 124
Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. 114
A 5'-truncated c-myc gene variant not associated with a risk of cancer 112
Genetic events in sporadic colorectal adenomas; K-ras and p53 heterozygous mutations are not sufficient for malignant progression 110
Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects 104
Base transitions are the most frequent genetic changes at P53 in gastric cancer 104
Loss of heterozygosity and K-ras gene mutations in gastric cancer 102
Study on aneuploidy and p53 mutations in astrocytomas 100
Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients 100
Aip-mutated acromegaly resistant to first-generation somatostatin analogs: Long-term control with pasireotide lar in two patients 100
Adiponectin affects the mechanical responses in strips from the mouse gastric fundus 99
Characterization of neuroendocrine tumors in heterozygous mutant MENX rats: A novel model of invasive medullary thyroid carcinoma 97
Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE): a study on pancreatic cancer 95
The significance of p53 mutations in human cancers 91
Mutation of the Cell Cycle Regulator p27kip1 Drives Pseudohypoxic Pheochromocytoma Development 87
Imaging pheochromocytoma in small animals: preclinical models to improve diagnosis and treatment 87
Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma 86
NET Models Meeting 2024 white paper: the current state of neuroendocrine tumour research models and our future aspirations 84
Animal models of MEN1 84
Angpt2/Tie2 autostimulatory loop controls tumorigenesis 82
Animal and Cell Culture Models of PPGLs – Achievements and Limitations 81
Adipocyte-specific tribbles pseudokinase 1 regulates plasma adiponectin and plasma lipids in mice 80
Identification of a Novel SSTR3 Full Agonist for the Treatment of Nonfunctioning Pituitary Adenomas 79
Animal models of multiple endocrine neoplasia 77
CDKN1B (p27) defects leading to pituitary tumors 76
Obesity and cancer – extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases 73
The glucocorticoid receptor in brown adipocytes is dispensable for control of energy homeostasis 73
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 72
Editorial: Stem Cells in Endocrine Tumors 71
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures 66
An AMP-activated protein kinase–stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice 65
Tribbles Genes in Gastric Cancer: A Tumor-Suppressive Role for TRIB2 64
The norepinephrine transporter as a putative predictive biomarker for PI3K/mTOR inhibition in pheochromocytoma. 63
miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance 63
Analysis of mammalian gene function through broad-based phenotypic screens across a consortium of mouse clinics 59
Multiple Endocrine Neoplasia Type 4 (MEN 4) 59
Opposing Effects of Cannabidiol in Patient-derived Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma Primary Cultures 58
Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses 57
Multiple Endocrine Neoplasia-Type 4 (MEN4) and Other MEN1-Like Syndromes 56
Gender-specific efficacy revealed by head-to-head comparison of pasireotide and octreotide in a representative in vivo model of nonfunctioning pituitary tumors 55
Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging 55
Systematic mapping of mitochondrial calcium uniporter channel (MCUC)-mediated calcium signaling networks 50
Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region 50
Targeting PI3K/mTOR signaling exerts potent antitumor activity in pheochromocytoma in vivo 49
Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome 47
Anti-secretory and anti-proliferative actions of next-generation dual subtype 2 and 5 somatostatin receptor ligands in neuroendocrine tumor models 46
Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma 45
Multiple Endocrine Neoplasia Type 4 44
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study 43
Morphology, Biochemistry, and Pathophysiology of MENX-Related Pheochromocytoma Recapitulate the Clinical Features 42
Primary Cell Culture Systems for Human Thyroid Studies 40
Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas 39
Ovarian hyperstimulation from ectopic hypersecretion of follicle stimulating hormone 39
Inceptor correlates with markers of prostate cancer progression and modulates insulin/IGF1 signaling and cancer cell migration 39
Simultaneous magnetic resonance imaging of pH, perfusion and renal filtration using hyperpolarized 13C-labelled Z-OMPD 38
SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary 37
Editorial: Obesity and metabolism in endocrine-related cancers 35
Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas 35
Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model 33
Multiple endocrine neoplasia type 4 (MEN4): a thorough update on the latest and least known men syndrome 32
Obesity in MENX Rats Is Accompanied by High Circulating Levels of Ghrelin and Improved Insulin Sensitivity 32
Mild chronic post-natal pain induces endocrine and metabolic alterations associated to enlargement in pituitary glands size in adult CD-1 male mice 27
Expanding the phenotype of multiple endocrine neoplasia type 5 (MEN5): Pituitary gigantism, myelolipoma and familial pheochromocytoma due to a germline pathogenic MAX variant 26
Totale 4.925
Categoria #
all - tutte 24.272
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.272


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022140 0 0 0 0 1 7 2 24 8 4 15 79
2022/2023550 44 47 4 31 63 59 2 31 246 3 12 8
2023/2024259 19 50 12 21 20 30 41 31 1 14 11 9
2024/2025879 20 64 9 20 8 83 74 64 212 34 83 208
2025/20261.940 153 121 209 172 240 119 343 131 153 158 71 70
2026/2027709 50 141 111 288 119 0 0 0 0 0 0 0
Totale 4.925